Personalis
PSNL Small CapHealthcare · Diagnostics & Research
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In ad
Personalis Stock at a Glance
Personalis (PSNL) is currently trading at $14.34 with a market capitalization of $1.5B. The 52-week range spans from $3.84 to $14.83; the current price is 3.3% below the yearly high. Year-over-year revenue growth stands at -24.9%.
💰 Dividend
Personalis currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
7 analysts rate Personalis (PSNL) on consensus: None. The average price target is $10.86, implying -24.29% from the current price. Analyst price targets range from $9.00 to $13.00.
Personalis: The Investment Case in Detail
Personalis (PSNL) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bear Case
Revenue is contracting at -24.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 2.24, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.
What to Watch Next
- The share is trading at 95.5% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- Solid balance sheet with low debt (D/E 15.22)
- –Revenue shrinking (-24.9% YoY)
- –Currently unprofitable
- –High volatility (Beta 2.24)
- –High short interest (16.75%)
- –Negative free cash flow
- –Price near 52-week high — limited upside cushion
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to above-average price swings, elevated short interest (16.75%).
Trading Data
Related Stocks in the Same Sector
Personalis (PSNL) 2026: 6,36 USD US Cancer-Genomics Specialist with NeXT Personal MRD-Monitoring Liquid-Biopsy Test, Moderna-Partnership and Tempus Strategic Investment
The Real Story
Personalis Inc. (NASDAQ: PSNL) is a Fremont, California-headquartered cancer-genomics-test-and-services company. Lead product: NeXT Personal, a tumor-informed liquid-biopsy minimal-residual-disease (MRD) monitoring test for early-detection of cancer-recurrence in breast, lung, colorectal, and immuno-oncology applications. Additional services: comprehensive-cancer-genomic-profiling (NeXT Dx) plus biopharma-services revenue.
The 2024–2025 inflection: NeXT Personal Medicare-coverage decision Q2 2025 (positive coverage decision for breast cancer monitoring) plus expansion into lung-and-colorectal-cancer-applications. Moderna strategic partnership for NeXT Personal in immuno-oncology-and-cancer-vaccine-development. Tempus AI (NASDAQ: TEM) holds approximately 4 percent strategic-investment.
What Smart Money Thinks
Personalis has biotech-genomics institutional base. Tempus AI at approximately 4 percent — strategic-investment signaling commercial collaboration. Casdin Capital at approximately 6,5 percent, RA Capital Management at approximately 4,8 percent. BlackRock at approximately 6,2 percent. Short-interest sits at approximately 12 percent of float as of May 2026.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
NeXT Personal Medicare-coverage Q2 2025 for breast cancer monitoring supports approximately 100-150 million USD peak-revenue from breast alone. Expansion to lung cancer (2026 Medicare-decision expected) and colorectal cancer creates 1+ billion USD cumulative peak-revenue opportunity by 2030.
Moderna partnership for NeXT Personal use in clinical trials of personalized-cancer-vaccines provides milestone-payment revenue plus structural-validation of the technology platform.
Tempus AI's strategic-investment plus commercial collaboration on cancer-genomics platforms validates Personalis's commercial-pathway and creates structural cross-sell-and-channel opportunities.
📉 The 3 Real Bear Points
NeXT Personal competes with Natera Signatera (more-established MRD test with Medicare coverage), Guardant Health, and Tempus xT. Competitive pricing-pressure could compress Personalis's market-share-trajectory.
Personalis burns approximately 60-90 million USD annually pre-profit. Continued capital-raise through 2026-2028 commercialization may dilute existing shareholders.
Medicare-coverage decisions for NeXT Personal lung and colorectal cancer expansions are not yet confirmed. Delayed-or-negative coverage decisions could compress peak-revenue trajectory.
Valuation in Context
Personalis at 6,36 USD per share with approximately 104,7 million shares outstanding has a market capitalization of approximately 666 million USD. With approximately 130 million USD net cash, enterprise value is approximately 540 million USD against trailing-twelve-month revenue of approximately 95 million USD (approximately 5,7x EV/sales).
Risk-adjusted-DCF on NeXT Personal peak-revenue 1+ billion USD by 2030 plus Moderna milestone-revenue plus services-segment supports fair-value range of 11-16 USD per share. Bear-case (competitive-share-loss, Medicare-coverage-slip) 3-4 USD. Bull-case (Medicare expansion executes) 18-25 USD over 24-36 months.
🗓️ Next 3 Catalyst Dates
-
2026 H2:
Lung cancer Medicare-coverage decision (expected H2 2026 per management guidance).
-
2026 Q4:
Q3 2026 earnings (early November 2026). Watch-items: NeXT Personal volume, Moderna milestone progression.
-
2027 Q1:
Fiscal-2026 full-year results plus fiscal-2027 guidance. Positive lung Medicare-coverage plus colorectal expansion progress would unlock 12-17 USD range.
💬 Daniel's Take
Personalis is a cancer-genomics MRD-monitoring specialist with NeXT Personal Medicare-coverage tailwind, Moderna strategic partnership, Tempus AI strategic investment, and event-driven 1+ billion USD peak-revenue opportunity. Position-sizing: 0,3–0,8 percent in thematic-biotech-genomics-event-driven sleeve.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Personalis?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news